Work

44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

Year: 2023

Type: article

Study design: Observational Study

Source: Journal of the American Academy of Dermatology

DOI: 10.1016/j.jaad.2023.07.251

Authors: April W. Armstrong, Laura K. Ferris, Kristina Callis Duffin, Jud C. Janak, Adam P. Sima, Thomas Eckmann, Huzefa Photowala, Manish Patel, Vishvas Garg, Bruce E. Strober

Institutions: University of Southern California, University of Pittsburgh, University of Utah, AbbVie (United States), Yale University

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Sanofi, Regeneron Pharmaceuticals

OpenAlex ID: W4387026441

FWCI:

Cites:

Cited by:

Related to: 10